Iris Hartley, M.D.

Iris Hartley, M.D., is an endocrinologist and clinician investigator in NIH’s Inter-Institute Endocrinology Training Program. Both her research and clinical work focus on rare metabolic bone diseases and disorders of mineral homeostasis. She is particularly interested in studying diseases related to aberrant fibroblast growth factor 23 (FGF23) homeostasis and applying them as tools for developing a broader understanding of FGF23 physiology. She was the lead associate investigator on the National Institute of Dental and Craniofacial Research’s (NIDCR’s) recently closed Single Patient Emergency Use of BGJ398 in the Treatment of Metastatic Phosphaturic Mesenchymal Tumor protocol, and is an associate investigator on NIDCR’s BGJ398 for the Treatment of Tumor-Induced Osteomalacia (18-D-0086) and Evaluation and Treatment of Bone and Mineral Disorders (01-D-0184). Dr. Hartley graduated from the University of Maryland Medical School, where she was inducted into the Alpha Omega Alpha Honor Medical Society. She completed her internal medicine clinical training at the University of Maryland Medical Center, followed by fellowship in adult endocrinology, diabetes, and metabolism at NIH under the mentorship of Dr. Michael T. Collins. She is board certified in internal medicine as well as in endocrinology, diabetes, and metabolism by the American Board of Internal Medicine.